|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
Cystic Fibrosis business from AstraZeneca
|
|
gptkbp:CEO
|
gptkb:Andrea_Recordati
|
|
gptkbp:country
|
gptkb:Italy
|
|
gptkbp:founded
|
1926
|
|
gptkbp:founder
|
gptkb:Giovanni_Recordati
|
|
gptkbp:headquarters_location
|
gptkb:Milan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Recordati
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:FTSE_Italia_Mid_Cap_Index
|
|
gptkbp:notableProduct
|
gptkb:Carbaglu
gptkb:Cosmegen
gptkb:Cystadane
gptkb:Cystagon
gptkb:Fenuril
gptkb:Flusapex
gptkb:Gopten
gptkb:Istin
gptkb:Isturisa
gptkb:Juxtapid
gptkb:Ledaga
gptkb:Lercanidipine
gptkb:Livazo
gptkb:Lomexin
gptkb:Normix
gptkb:Pitavastatin
gptkb:Signifor
gptkb:Silodosin
gptkb:Silodyx
gptkb:TransAct_LAT
gptkb:Urbason
gptkb:Zanidip
|
|
gptkbp:numberOfEmployees
|
over 4,000
|
|
gptkbp:operatesIn
|
gptkb:Asia
gptkb:Europe
gptkb:Latin_America
gptkb:North_America
|
|
gptkbp:products
|
pharmaceutical drugs
rare disease treatments
|
|
gptkbp:revenue
|
€1.85 billion (2022)
|
|
gptkbp:stockExchange
|
Borsa Italiana
|
|
gptkbp:stockSymbol
|
gptkb:REC
|
|
gptkbp:subsidiary
|
gptkb:Orphan_Europe
gptkb:Recordati_Rare_Diseases
|
|
gptkbp:website
|
https://www.recordati.com/
|
|
gptkbp:bfsParent
|
gptkb:CVC_Capital_Partners
|
|
gptkbp:bfsLayer
|
6
|